Target
CDK 4 and 6
4 abstracts
Abstract
Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG Pediatric MATCH trial Arm I (APEC1621I).Org: Department of Pediatrics, University of Colorado and Center for Cancer and Blood Disorders, Children’s Hospital Colorado, Aurora, CO, University of Michigan, Ann Arbor, MI, Mayo Clinic, Rochester, MN, Children's Oncology Group, Monrovia, CA, Univ of Southern California/Children's Oncology Group, Arcadia, CA, Texas Children's Cancer and Hematology Center, Houston, TX, St. Jude Children's Research Hospital, Memphis, TN, Seattle Children's Hospital, Seattle, WA, National Cancer Institute, Rockville, MD, Frederick National Laboratory for Cancer Research, Frederick, MD, Center for Biomedical Informatics & Information Technology, NCI, NIH, Bethesda, MD, MD Anderson Cancer Center, Houston, TX, Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, National Cancer Institute Center for Bioinformatics, Rockville, MD, Dana-Farber Cancer Institute, Boston, MA, Cancer Therapy Evaluation Program, NCI, Bethesda, MD, Texas Children's Cancer Center/Baylor College of Medicine, Houston, TX,
Abstract
LITESPARK-024: Randomized phase 1/2 study of belzutifan with or without palbociclib for treatment of advanced renal cell carcinoma (RCC).Org: Beth Israel Deaconess Medical Center, Rambam Health Care Campus, Huntsman Cancer Institute, Georgetown Lombardi Comprehensive Cancer Center, Merck & Co., Inc.,
Abstract
Outcome of second-line treatment after CDK4/6 inhibitors in hormonal-positive HER-2 negative metastatic breast cancer: Single institution experience.Org: King Abdulla Medical City/Makkah, Oncology Center, Medica Sur Hospital, King Abdullah Medical City, Mansoura University, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,
Abstract
A phase 2 basket trial of an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MAP2K1/2 ERK1/2, and NF1.Org: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Indiana University Simon Cancer Center and Roudebush VAMC, Department of Hematology/Oncology, IU Simon Comprehensive Cancer Center, Melvin and Bren Simon Cancer Center, Indianapolis, IN,